HCC model for adoptive cell therapy (GenuineSelect-HCC-act)

T cell receptor (TCR) engineered T cells, chimeric antigen receptors (CAR)-NK cells, and CAR-T cells that target tumor-associated antigens (TAAs) such as GPC3, AFP, EpCam, or MET, are promising technologies and are effective in clinical trials for advanced HCC. Nevertheless, severe off-tumor toxicity has been observed in most clinical trials because these TAAs are also present on non-malignant cells. To mitigate the onset of this off-tumor toxicity and to improve the outcomes, dual-targeting CAR-T and CAR-NK cells were designed to target simultaneously two TAAs of interest. Because patterns of TAAs expression in solid tumors are highly heterogeneous and there are wide variations among patients, specific dual-targeting CAR-T/CAR-NK cells must be designed for an optimal efficacy.

PredictCan Biotechnologies uses the cell educating technology to generate HCC educated spheroids that express patient specific TAAs patterns for dual-targeting CAR-T/CAR-NK cells design and efficacy testing.